Nulibry (Fosdenopterin)

Fosdenopterin, the active ingredient in Nulibry, is a cPMP analog presented as an intravenous solution for intravenous use. It treats molybdenum cofactor deficiency type A, a rare metabolic disorder, in affected patients. GNH USA supplies Nulibry as a licensed, GDP-compliant international pharmaceutical supplier serving hospitals worldwide.

Nulibry is used in the treatment of molybdenum cofactor deficiency type A, a rare inherited metabolic disorder affecting enzyme activity.

Molybdenum cofactor deficiency type A: Restores molybdenum cofactor activity by providing cyclic pyranopterin monophosphate, improving enzyme function and reducing disease manifestations.

Common Side Effects: - Fever or chills during infusion - Nausea or vomiting - Diarrhea or abdominal discomfort - Rash or mild skin irritation - Transient hypotension - Elevated liver enzymes

Serious or Rare Side Effects: - Anaphylactic reaction - Severe infusion‑related anaphylactoid response - Hepatic failure or severe liver injury - Significant neutropenia or thrombocytopenia - Life‑threatening hypersensitivity reactions

Precautions for Nulibry include careful monitoring and specific actions to ensure patient safety. - Monitor liver function: Perform baseline and periodic liver enzyme tests. - Observe blood counts: Check complete blood count before and during therapy. - Assess for hypersensitivity: Watch for signs of allergic reaction during infusion. - Use appropriate infusion set: Employ low‑dead‑space tubing to minimize contamination. - Avoid use in patients with known Fosdenopterin hypersensitivity. - Store at 2-8°C: Keep refrigerated, protect from light, do not freeze or shake.

Potential drug interactions with Nulibry are categorized to guide clinical management. Major Interactions (Avoid): - Concurrent use with other cPMP analogs: May cause additive toxicity. - Known hypersensitivity to any formulation component: Risk of severe reaction. - Co‑administration with experimental MoCD therapies: Uncertain safety profile. Moderate Interactions (Monitor Closely): - Nephrotoxic agents: Monitor renal function during combined therapy. - Anticoagulants: Observe for increased bleeding risk during infusion. - Other intravenous biologics: Assess compatibility and infusion timing.